Compared to docetaxel, atezolizumab was associated with an increase in median OS (13.8 vs. 9.6 months, respectively), the effect being particularly evident in patients with high percentage of tumor cells with PD-L1 expression (mOS 15.7 vs. 10.3 months) and independent of the histological subtype of lung cancer. Here, CD274 is linked to lung cancer.